{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:54:18Z","timestamp":1775217258212,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000066","name":"U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["Z01-ES-101585"],"award-info":[{"award-number":["Z01-ES-101585"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Deficiency in GLI-similar 3 (GLIS3) in humans and mice causes polycystic kidney disease (PKD). We previously reported that\n                    <jats:italic>Glis3-<\/jats:italic>\n                    knockout (KO) kidneys undergo metabolic reprogramming and remain more reliant on aerobic glycolysis. Here, to understand the mechanism by which GLIS3 controls this process, we analyzed its role in regulating glycolytic gene expression using transcriptomics and cistromics. Transcriptomic analysis revealed increased expression of key glycolytic genes and reduced expression of several gluconeogenic genes in\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO compared with wild-type kidneys. Chromatin immunoprecipitation followed by sequencing analysis showed that many of these genes were directly regulated by GLIS3 in coordination with the transcription factor, HNF-1B.\n                    <jats:italic>Pkm<\/jats:italic>\n                    emerged as a key upregulated glycolytic GLIS3 target gene, which via alternative splicing generates two protein isoforms, PKM1 and PKM2. Expression of\n                    <jats:italic>Pkm<\/jats:italic>\n                    and the dimeric form of PKM2, which promotes aerobic glycolysis, was elevated in\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO kidneys, whereas exogenous GLIS3 expression in primary\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO renal epithelial cells suppressed\n                    <jats:italic>Pkm<\/jats:italic>\n                    expression. Phosphorylation of PKM2 at Y105 and S37, which stimulate dimer formation, nuclear localization and aerobic glycolysis, is increased in\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO kidneys, consistent with a role for PKM2 in metabolic reprogramming and cyst formation. Consistent with this, siRNA-mediated knockdown of PKM2 in\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO renal epithelial cells suppressed spheroid growth and glycolytic activity. In addition, pharmacological inhibition of PKM2 with compound 3K in GLIS3-deficient spheroid cultures and\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO kidneys significantly reduced spheroid size, cyst number and cystic area. Our study identifies GLIS3 as a novel regulator of glycolysis and PKM2 function, whose dysregulation contributes to metabolic reprogramming and cystogenesis in\n                    <jats:italic>Glis3<\/jats:italic>\n                    -KO kidneys.\n                  <\/jats:p>","DOI":"10.1038\/s12276-026-01676-5","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:50:16Z","timestamp":1773381016000},"page":"932-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulation of PKM2 expression and function by GLIS3 during metabolic reprogramming in polycystic kidneys"],"prefix":"10.1038","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5302-2826","authenticated-orcid":false,"given":"Justin B.","family":"Collier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong Soon","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara A.","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanushree","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitrangda","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-4445","authenticated-orcid":false,"given":"Anton M.","family":"Jetten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"1676_CR1","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1093\/nar\/gkg776","volume":"31","author":"YS Kim","year":"2003","unstructured":"Kim, Y. S., Nakanishi, G., Lewandoski, M. & Jetten, A. M. GLIS3, a novel member of the GLIS subfamily of Kr\u00fcppel-like zinc finger proteins with repressor and activation functions. Nucleic Acids Res. 31, 5513\u20135525 (2003).","journal-title":"Nucleic Acids Res."},{"key":"1676_CR2","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1007\/s00018-018-2841-9","volume":"75","author":"AM Jetten","year":"2018","unstructured":"Jetten, A. M. GLIS1-3 transcription factors: critical roles in the regulation of multiple physiological processes and diseases. Cell Mol. Life Sci. 75, 3473\u20133494 (2018).","journal-title":"Cell Mol. Life Sci."},{"key":"1676_CR3","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1128\/MCB.01620-08","volume":"29","author":"HS Kang","year":"2009","unstructured":"Kang, H. S., Beak, J. Y., Kim, Y. S., Herbert, R. & Jetten, A. M. Glis3 is associated with primary cilia and Wwtr1\/TAZ and implicated in polycystic kidney disease. Mol. Cell Biol. 29, 2556\u20132569 (2009).","journal-title":"Mol. Cell Biol."},{"key":"1676_CR4","doi-asserted-by":"publisher","first-page":"107632","DOI":"10.1016\/j.pharmthera.2020.107632","volume":"215","author":"DW Scoville","year":"2020","unstructured":"Scoville, D. W., Kang, H. S. & Jetten, A. M. Transcription factor GLIS3: critical roles in thyroid hormone biosynthesis, hypothyroidism, pancreatic beta cells and diabetes. Pharmacol. Ther. 215, 107632 (2020).","journal-title":"Pharmacol. Ther."},{"key":"1676_CR5","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13578-023-00979-8","volume":"13","author":"HS Kang","year":"2023","unstructured":"Kang, H. S., Grimm, S. A., Jothi, R., Santisteban, P. & Jetten, A. M. GLIS3 regulates transcription of thyroid hormone biosynthetic genes in coordination with other thyroid transcription factors. Cell Biosci. 13, 32 (2023).","journal-title":"Cell Biosci."},{"key":"1676_CR6","doi-asserted-by":"publisher","first-page":"4326","DOI":"10.1172\/JCI94417","volume":"127","author":"HS Kang","year":"2017","unstructured":"Kang, H. S. et al. GLIS3 is indispensable for TSH\/TSHR-dependent thyroid hormone biosynthesis and follicular cell proliferation. J. Clin. Invest. 127, 4326\u20134337 (2017).","journal-title":"J. Clin. Invest."},{"key":"1676_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ng1802","volume":"38","author":"V Sen\u00e9e","year":"2006","unstructured":"Sen\u00e9e, V. et al. Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. Nat. Genet. 38, 682\u2013687 (2006).","journal-title":"Nat. Genet."},{"key":"1676_CR8","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.febslet.2009.05.039","volume":"583","author":"N Watanabe","year":"2009","unstructured":"Watanabe, N. et al. A murine model of neonatal diabetes mellitus in Glis3-deficient mice. FEBS Lett. 583, 2108\u20132113 (2009).","journal-title":"FEBS Lett."},{"key":"1676_CR9","doi-asserted-by":"publisher","first-page":"E1362","DOI":"10.1210\/jc.2015-1827","volume":"100","author":"P Dimitri","year":"2015","unstructured":"Dimitri, P. et al. Expanding the clinical spectrum associated with GLIS3 mutations. J. Clin. Endocrinol. Metab. 100, E1362\u2013E1369 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1676_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.md.0000200165.90373.9a","volume":"85","author":"M Adeva","year":"2006","unstructured":"Adeva, M. et al. Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD). Medicine 85, 1\u201321 (2006).","journal-title":"Medicine"},{"key":"1676_CR11","doi-asserted-by":"publisher","first-page":"102052","DOI":"10.1016\/j.molmet.2024.102052","volume":"90","author":"JB Collier","year":"2024","unstructured":"Collier, J. B. et al. GLIS3: a novel transcriptional regulator of mitochondrial functions and metabolic reprogramming in postnatal kidney and polycystic kidney disease. Mol. Metab. 90, 102052 (2024).","journal-title":"Mol. Metab."},{"key":"1676_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/nbm.3281","volume":"28","author":"L Xie","year":"2015","unstructured":"Xie, L. et al. 4D MRI of polycystic kidneys from rapamycin-treated Glis3-deficient mice. NMR Biomed. 28, 546\u2013554 (2015).","journal-title":"NMR Biomed."},{"key":"1676_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Martinez-Reyes","year":"2020","unstructured":"Martinez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 11, 102 (2020).","journal-title":"Nat. Commun."},{"key":"1676_CR14","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","volume":"14","author":"V Padovano","year":"2018","unstructured":"Padovano, V., Podrini, C., Boletta, A. & Caplan, M. J. Metabolism and mitochondria in polycystic kidney disease research and therapy. Nat. Rev. Nephrol. 14, 678\u2013687 (2018).","journal-title":"Nat. Rev. Nephrol."},{"key":"1676_CR15","doi-asserted-by":"publisher","first-page":"109495","DOI":"10.1016\/j.cellsig.2019.109495","volume":"67","author":"C Podrini","year":"2020","unstructured":"Podrini, C., Cassina, L. & Boletta, A. Metabolic reprogramming and the role of mitochondria in polycystic kidney disease. Cell. Signal. 67, 109495 (2020).","journal-title":"Cell. Signal."},{"key":"1676_CR16","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41581-019-0183-y","volume":"15","author":"LF Menezes","year":"2019","unstructured":"Menezes, L. F. & Germino, G. G. The pathobiology of polycystic kidney disease from a metabolic viewpoint. Nat. Rev. Nephrol. 15, 735\u2013749 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"1676_CR17","doi-asserted-by":"crossref","unstructured":"Ishimoto, Y. et al. Mitochondrial abnormality facilitates cyst formation in autosomal dominant polycystic kidney disease. Mol. Cell Biol. 37, e00337-17 (2017).","DOI":"10.1128\/MCB.00337-17"},{"key":"1676_CR18","doi-asserted-by":"publisher","first-page":"1126055","DOI":"10.3389\/fmolb.2023.1126055","volume":"10","author":"I Bakaj","year":"2023","unstructured":"Bakaj, I. & Pocai, A. Metabolism-based approaches for autosomal dominant polycystic kidney disease. Front. Mol. Biosci. 10, 1126055 (2023).","journal-title":"Front. Mol. Biosci."},{"key":"1676_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/nep.13957","volume":"26","author":"S Saravanabavan","year":"2021","unstructured":"Saravanabavan, S. & Rangan, G. K. Possible role of the mitochondrial genome in the pathogenesis of autosomal dominant polycystic kidney disease. Nephrology 26, 920\u2013930 (2021).","journal-title":"Nephrology"},{"key":"1676_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2215\/CJN.13291019","volume":"15","author":"KL Nowak","year":"2020","unstructured":"Nowak, K. L. & Hopp, K. Metabolic reprogramming in autosomal dominant polycystic kidney disease: evidence and therapeutic potential. Clin. J. Am. Soc. Nephrol. 15, 577\u2013584 (2020).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"1676_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27\u201347 (2016).","journal-title":"Cell Metab."},{"key":"1676_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488\u2013493 (2013).","journal-title":"Nat. Med."},{"key":"1676_CR23","doi-asserted-by":"crossref","unstructured":"Puckett, D. L., Alquraishi, M., Chowanadisai, W. & Bettaieb, A. The role of PKM2 in metabolic reprogramming: insights into the regulatory roles of non-coding RNAs. Int. J. Mol. Sci. 22, 1171 (2021).","DOI":"10.3390\/ijms22031171"},{"key":"1676_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fonc.2020.00159","volume":"10","author":"K Zahra","year":"2020","unstructured":"Zahra, K., Dey, T., Ashish, Mishra, S. P. & Pandey, U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front. Oncol. 10, 159 (2020).","journal-title":"Front. Oncol."},{"key":"1676_CR25","doi-asserted-by":"publisher","first-page":"13807","DOI":"10.1016\/S0021-9258(18)67091-7","volume":"261","author":"T Noguchi","year":"1986","unstructured":"Noguchi, T., Inoue, H. & Tanaka, T. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J. Biol. Chem. 261, 13807\u201313812 (1986).","journal-title":"J. Biol. Chem."},{"key":"1676_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1432-1033.1991.tb15991.x","volume":"198","author":"M Takenaka","year":"1991","unstructured":"Takenaka, M. et al. Isolation and characterization of the human pyruvate kinase M gene. Eur. J. Biochem. 198, 101\u2013106 (1991).","journal-title":"Eur. J. Biochem."},{"key":"1676_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.canlet.2020.11.018","volume":"503","author":"S Zhu","year":"2021","unstructured":"Zhu, S. et al. Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics. Cancer Lett. 503, 240\u2013248 (2021).","journal-title":"Cancer Lett."},{"key":"1676_CR28","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13578-019-0317-8","volume":"9","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z. et al. PKM2, function and expression and regulation. Cell Biosci. 9, 52 (2019).","journal-title":"Cell Biosci."},{"key":"1676_CR29","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ncb2629","volume":"14","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14, 1295\u20131304 (2012).","journal-title":"Nat. Cell Biol."},{"key":"1676_CR30","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.4161\/cc.26182","volume":"12","author":"W Yang","year":"2013","unstructured":"Yang, W. & Lu, Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12, 3154\u20133158 (2013).","journal-title":"Cell Cycle"},{"key":"1676_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell 150, 685\u2013696 (2012).","journal-title":"Cell"},{"key":"1676_CR32","doi-asserted-by":"publisher","first-page":"ra73","DOI":"10.1126\/scisignal.2000431","volume":"2","author":"T Hitosugi","year":"2009","unstructured":"Hitosugi, T. et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal 2, ra73 (2009).","journal-title":"Sci. Signal"},{"key":"1676_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00018-024-05113-6","volume":"81","author":"HS Kang","year":"2024","unstructured":"Kang, H. S., Grimm, S. A., Liao, X. H. & Jetten, A. M. GLIS3 expression in the thyroid gland in relation to TSH signaling and regulation of gene expression. Cell Mol. Life Sci. 81, 65 (2024).","journal-title":"Cell Mol. Life Sci."},{"key":"1676_CR34","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.celrep.2019.08.093","volume":"29","author":"S Farris","year":"2019","unstructured":"Farris, S. et al. Hippocampal subregions express distinct dendritic transcriptomes that reveal differences in mitochondrial function in CA2. Cell Rep. 29, 522\u2013539 (2019).","journal-title":"Cell Rep."},{"key":"1676_CR35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/JME-20-0082","volume":"65","author":"DW Scoville","year":"2020","unstructured":"Scoville, D. W., Gruzdev, A. & Jetten, A. M. Identification of a novel lncRNA (G3R1) regulated by GLIS3 in pancreatic \u03b2-cells. J. Mol. Endocrinol. 65, 59\u201367 (2020).","journal-title":"J. Mol. Endocrinol."},{"key":"1676_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18104-5","volume":"11","author":"I Cabrita","year":"2020","unstructured":"Cabrita, I. et al. Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo. Nat. Commun. 11, 4320 (2020).","journal-title":"Nat. Commun."},{"key":"1676_CR37","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.kint.2023.01.026","volume":"103","author":"PG Dagorn","year":"2023","unstructured":"Dagorn, P. G. et al. A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of autosomal dominant polycystic kidney disease. Kidney Int. 103, 917\u2013929 (2023).","journal-title":"Kidney Int."},{"key":"1676_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10059-012-0109-z","volume":"34","author":"YS Kim","year":"2012","unstructured":"Kim, Y. S. et al. Glis3 regulates neurogenin 3 expression in pancreatic \u03b2-cells and interacts with its activator, Hnf6. Mol. Cells 34, 193\u2013200 (2012).","journal-title":"Mol. Cells"},{"key":"1676_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004331","volume":"10","author":"Y Takeda","year":"2014","unstructured":"Takeda, Y. et al. Retinoic acid-related orphan receptor \u03b3 (ROR\u03b3): a novel participant in the diurnal regulation of hepatic gluconeogenesis and insulin sensitivity. PLoS Genet. 10, e1004331 (2014).","journal-title":"PLoS Genet."},{"key":"1676_CR40","doi-asserted-by":"crossref","unstructured":"Scoville, D. W., Lichti-Kaiser, K., Grimm, S. & Jetten, A. GLIS3 binds pancreatic beta cell regulatory regions alongside other islet transcription factors. J. Endocrinol. 243, 1\u201314 (2019).","DOI":"10.1530\/JOE-19-0182"},{"key":"1676_CR41","doi-asserted-by":"publisher","first-page":"1376252","DOI":"10.3389\/fphar.2024.1376252","volume":"15","author":"DQ Chen","year":"2024","unstructured":"Chen, D. Q., Han, J., Liu, H., Feng, K. & Li, P. Targeting pyruvate kinase M2 for the treatment of kidney disease. Front. Pharmacol. 15, 1376252 (2024).","journal-title":"Front. Pharmacol."},{"key":"1676_CR42","doi-asserted-by":"publisher","first-page":"7702681","DOI":"10.1155\/2022\/7702681","volume":"2022","author":"J Gao","year":"2022","unstructured":"Gao, J., Zhao, Y., Li, T., Gan, X. & Yu, H. The role of PKM2 in the regulation of mitochondrial function: focus on mitochondrial metabolism, oxidative stress, dynamic, and apoptosis. PKM2 in mitochondrial function. Oxid. Med. Cell Longev. 2022, 7702681 (2022).","journal-title":"Oxid. Med. Cell Longev."},{"key":"1676_CR43","doi-asserted-by":"publisher","first-page":"122719","DOI":"10.1016\/j.lfs.2024.122719","volume":"349","author":"P Singla","year":"2024","unstructured":"Singla, P. & Jain, A. Deciphering the complex landscape of post-translational modifications on PKM2: implications in head and neck cancer pathogenesis. Life Sci. 349, 122719 (2024).","journal-title":"Life Sci."},{"key":"1676_CR44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fonc.2018.00022","volume":"8","author":"G Prakasam","year":"2018","unstructured":"Prakasam, G., Iqbal, M. A., Bamezai, R. N. K. & Mazurek, S. Posttranslational modifications of pyruvate kinase M2: tweaks that benefit cancer. Front. Oncol. 8, 22 (2018).","journal-title":"Front. Oncol."},{"key":"1676_CR45","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1016\/j.apsb.2024.04.024","volume":"14","author":"C Peng","year":"2024","unstructured":"Peng, C. et al. KHK-A promotes fructose-dependent colorectal cancer liver metastasis by facilitating the phosphorylation and translocation of PKM2. Acta Pharm. Sin. B 14, 2959\u20132976 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"1676_CR46","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/0008-5472.CAN-20-4190","volume":"81","author":"M Apostolidi","year":"2021","unstructured":"Apostolidi, M. et al. Targeting pyruvate kinase M2 phosphorylation reverses aggressive cancer phenotypes. Cancer Res. 81, 4346\u20134359 (2021).","journal-title":"Cancer Res."},{"key":"1676_CR47","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1038\/nprot.2014.181","volume":"9","author":"RH Giles","year":"2014","unstructured":"Giles, R. H., Ajzenberg, H. & Jackson, P. K. 3D spheroid model of mIMCD3 cells for studying ciliopathies and renal epithelial disorders. Nat. Protoc. 9, 2725\u20132731 (2014).","journal-title":"Nat. Protoc."},{"key":"1676_CR48","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ejmech.2017.06.064","volume":"138","author":"X Ning","year":"2017","unstructured":"Ning, X. et al. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase. Eur. J. Med. Chem. 138, 343\u2013352 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"1676_CR49","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/ajmg.a.37680","volume":"170","author":"P Dimitri","year":"2016","unstructured":"Dimitri, P. et al. An emerging, recognizable facial phenotype in association with mutations in GLI-similar 3 (GLIS3). Am. J. Med. Genet. A 170, 1918\u20131923 (2016).","journal-title":"Am. J. Med. Genet. A"},{"key":"1676_CR50","doi-asserted-by":"publisher","first-page":"109568","DOI":"10.1016\/j.cellsig.2020.109568","volume":"71","author":"A Shao","year":"2020","unstructured":"Shao, A., Chan, S. C. & Igarashi, P. Role of transcription factor hepatocyte nuclear factor-1beta in polycystic kidney disease. Cell. Signal. 71, 109568 (2020).","journal-title":"Cell. Signal."},{"key":"1676_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41421-023-00633-0","volume":"10","author":"LJ Liang","year":"2024","unstructured":"Liang, L. J. et al. CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in non-small cell lung cancer. Cell Discov. 10, 13 (2024).","journal-title":"Cell Discov."},{"key":"1676_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","volume":"39","author":"J Feng","year":"2020","unstructured":"Feng, J. et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 39, 126 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1676_CR53","doi-asserted-by":"publisher","first-page":"242513","DOI":"10.1155\/2013\/242513","volume":"2013","author":"N Wong","year":"2013","unstructured":"Wong, N., De Melo, J. & Tang, D. PKM2, a central point of regulation in cancer metabolism. Int. J. Cell Biol. 2013, 242513 (2013).","journal-title":"Int. J. Cell Biol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01676-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01676-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01676-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:02:13Z","timestamp":1775214133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-026-01676-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["1676"],"URL":"https:\/\/doi.org\/10.1038\/s12276-026-01676-5","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}